Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study

This trial was conducted to assess the activity and tolerability of the gemcitabine, epirubicin, taxol triplet combination in patients with operable breast cancer. After core biopsy, 43 women with stage II–IIIA breast cancer were treated with gemcitabine 1000 mg m(−2) over 30 min on days 1 and 4, ep...

Descripción completa

Detalles Bibliográficos
Autores principales: Conte, P F, Donati, S, Gennari, A, Guarneri, V, Orlandini, C, Rondini, M, Roncella, M, Marini, L, Collecchi, P, Viacava, P, Naccarato, A G, Degli Esposti, R, Bonardi, S, Bottini, A, Saracchini, S, Tumolo, S, Gullo, G, Santoro, A, Crino, L
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361588/
https://www.ncbi.nlm.nih.gov/pubmed/16052214
http://dx.doi.org/10.1038/sj.bjc.6602723

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361588/
https://www.ncbi.nlm.nih.gov/pubmed/16052214
http://dx.doi.org/10.1038/sj.bjc.6602723

Ejemplares similares